Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2019
Historique:
pubmed: 3 9 2019
medline: 6 11 2020
entrez: 3 9 2019
Statut: ppublish

Résumé

At autopsy, individuals with Alzheimer's disease (AD) exhibit heterogeneity in the distribution of neurofibrillary tangles in neocortical and hippocampal regions. Subtypes of AD, defined using an algorithm based on the relative number of tangle counts in these regions, have been proposed-hippocampal sparing (relative sparing of the hippocampus but high cortical load), limbic predominant (high hippocampal load but lower load in association cortices), and typical (balanced neurofibrillary tangles counts in the hippocampus and association cortices) AD-and shown to be associated with distinct antemortem clinical phenotypes. The ability to distinguish these AD subtypes from the more typical tau signature in vivo could have important implications for clinical research. Flortaucipir positron emission tomography (PET) images acquired from 45 amyloid-positive participants, defined clinically as mild cognitive impairment or AD, aged 50-92 years, 56% female, and estimated to be Braak V-VI based on their PET pattern of tau pathology, were studied. By translating the neuropathologic algorithm to flortaucipir PET scans, patterns of tau pathology consistent with autopsy findings, and with a similar prevalence, were identified in vivo. 6/45 (13%) participants were identified as hippocampal sparing and 6/45 (13%) as limbic predominant AD subtypes. Hippocampal sparing participants were significantly younger than those assigned to the other two subtypes. Worse performance on delayed recall was associated with increased hippocampal tau signal, and worse performance on the trail making test B-A was associated with lower values of the hippocampus to cortex ratio. Prospective studies can further validate the flortaucipir SUVR cut-points and the phenotype of the corresponding AD subtypes.

Identifiants

pubmed: 31476153
pii: JAD190264
doi: 10.3233/JAD-190264
doi:

Substances chimiques

Carbolines 0
Radiopharmaceuticals 0
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole J09QS3Z3WB

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1037-1048

Auteurs

Arnaud Charil (A)

Eli Lilly and Company, Indianapolis, IN, USA.

Sergey Shcherbinin (S)

Eli Lilly and Company, Indianapolis, IN, USA.

Sudeepti Southekal (S)

Avid Radiopharmaceuticals, Philadelphia, PA, USA.

Michael D Devous (MD)

Avid Radiopharmaceuticals, Philadelphia, PA, USA.

Mark Mintun (M)

Eli Lilly and Company, Indianapolis, IN, USA.
Avid Radiopharmaceuticals, Philadelphia, PA, USA.

Melissa E Murray (ME)

Mayo Clinic, Jacksonville, FL, USA.

Bradley B Miller (BB)

Eli Lilly and Company, Indianapolis, IN, USA.

Adam J Schwarz (AJ)

Eli Lilly and Company, Indianapolis, IN, USA.
Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, IN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH